TargetFish industry forum on DNA vaccination: where do we stand and what's next?

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

TargetFish industry forum on DNA vaccination : where do we stand and what's next? / Wiegertjes, G. F.; Forlenza, M.; Lorenzen, N.; Collet, B.; Fischer, U.; Tafalla, C.; Evensen, O.; Smith, P.; Christofilogiannis, P.; Henriksen, N. H.

In: Bulletin of The European Association of Fish Pathologists, Vol. 38, No. 3, 2018, p. 116-121.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Wiegertjes, GF, Forlenza, M, Lorenzen, N, Collet, B, Fischer, U, Tafalla, C, Evensen, O, Smith, P, Christofilogiannis, P & Henriksen, NH 2018, 'TargetFish industry forum on DNA vaccination: where do we stand and what's next?', Bulletin of The European Association of Fish Pathologists, vol. 38, no. 3, pp. 116-121.

APA

Wiegertjes, G. F., Forlenza, M., Lorenzen, N., Collet, B., Fischer, U., Tafalla, C., ... Henriksen, N. H. (2018). TargetFish industry forum on DNA vaccination: where do we stand and what's next? Bulletin of The European Association of Fish Pathologists, 38(3), 116-121.

CBE

Wiegertjes GF, Forlenza M, Lorenzen N, Collet B, Fischer U, Tafalla C, Evensen O, Smith P, Christofilogiannis P, Henriksen NH. 2018. TargetFish industry forum on DNA vaccination: where do we stand and what's next?. Bulletin of The European Association of Fish Pathologists. 38(3):116-121.

MLA

Wiegertjes, G. F. et al. "TargetFish industry forum on DNA vaccination: where do we stand and what's next?". Bulletin of The European Association of Fish Pathologists. 2018, 38(3). 116-121.

Vancouver

Wiegertjes GF, Forlenza M, Lorenzen N, Collet B, Fischer U, Tafalla C et al. TargetFish industry forum on DNA vaccination: where do we stand and what's next? Bulletin of The European Association of Fish Pathologists. 2018;38(3):116-121.

Author

Wiegertjes, G. F. ; Forlenza, M. ; Lorenzen, N. ; Collet, B. ; Fischer, U. ; Tafalla, C. ; Evensen, O. ; Smith, P. ; Christofilogiannis, P. ; Henriksen, N. H. / TargetFish industry forum on DNA vaccination : where do we stand and what's next?. In: Bulletin of The European Association of Fish Pathologists. 2018 ; Vol. 38, No. 3. pp. 116-121.

Bibtex

@article{043a1864ae724be799d418aa156b4454,
title = "TargetFish industry forum on DNA vaccination: where do we stand and what's next?",
abstract = "Maybe most characteristic of the TargetFish project, which kicked off some five years ago with 30 partners from 10 EU member states, two associated countries (Norway, Israel) and one international cooperation partner country (Chile), has been the close cooperation between research groups and enterprises; more or less equally represented in this large consortium. In this respect, TargetFish has been revolutionary validating by this close cooperation fundamental knowledge for the development of next generation vaccines and different routes of vaccine administration. TargetFish had the ambition to demonstrate market applicability of improved vaccines or new prototype vaccines that would come forward from the project. Via frequent joint meetings of its partners, be it research group or enterprise, TargetFish aimed to drive vaccine development in an industrial applicable way. This could facilitate adoption of new intellectual property and stimulate the presentation of new fish vaccines on the market. The industry forum has been a platform for a continuing validation of the applied potential of the research outcomes. Workshops were organised at the different EAFP meetings to communicate the validation process to those not directly involved with the project but interested in the fish vaccine market. After a kick-off meeting during the EAFP in Tampere, Finland fours years ago and a second meeting at the EAFP in Las Palmas, Spain, two years ago, at the present EAFP in Belfast, Northern Ireland a final meeting was organised. This report is a summary of the 'Industrial Forum workshop' held at the EAFP in Belfast 2017 and provides a short overview of the highlights presented to, and discussed with, those present and interested in DNA vaccine development, policies and laws, production and delivery routes.",
author = "Wiegertjes, {G. F.} and M. Forlenza and N. Lorenzen and B. Collet and U. Fischer and C. Tafalla and O. Evensen and P. Smith and P. Christofilogiannis and Henriksen, {N. H.}",
year = "2018",
language = "English",
volume = "38",
pages = "116--121",
journal = "Bulletin of The European Association of Fish Pathologists",
issn = "0108-0288",
publisher = "European Association of Fish Pathologists",
number = "3",

}

RIS

TY - JOUR

T1 - TargetFish industry forum on DNA vaccination

T2 - where do we stand and what's next?

AU - Wiegertjes, G. F.

AU - Forlenza, M.

AU - Lorenzen, N.

AU - Collet, B.

AU - Fischer, U.

AU - Tafalla, C.

AU - Evensen, O.

AU - Smith, P.

AU - Christofilogiannis, P.

AU - Henriksen, N. H.

PY - 2018

Y1 - 2018

N2 - Maybe most characteristic of the TargetFish project, which kicked off some five years ago with 30 partners from 10 EU member states, two associated countries (Norway, Israel) and one international cooperation partner country (Chile), has been the close cooperation between research groups and enterprises; more or less equally represented in this large consortium. In this respect, TargetFish has been revolutionary validating by this close cooperation fundamental knowledge for the development of next generation vaccines and different routes of vaccine administration. TargetFish had the ambition to demonstrate market applicability of improved vaccines or new prototype vaccines that would come forward from the project. Via frequent joint meetings of its partners, be it research group or enterprise, TargetFish aimed to drive vaccine development in an industrial applicable way. This could facilitate adoption of new intellectual property and stimulate the presentation of new fish vaccines on the market. The industry forum has been a platform for a continuing validation of the applied potential of the research outcomes. Workshops were organised at the different EAFP meetings to communicate the validation process to those not directly involved with the project but interested in the fish vaccine market. After a kick-off meeting during the EAFP in Tampere, Finland fours years ago and a second meeting at the EAFP in Las Palmas, Spain, two years ago, at the present EAFP in Belfast, Northern Ireland a final meeting was organised. This report is a summary of the 'Industrial Forum workshop' held at the EAFP in Belfast 2017 and provides a short overview of the highlights presented to, and discussed with, those present and interested in DNA vaccine development, policies and laws, production and delivery routes.

AB - Maybe most characteristic of the TargetFish project, which kicked off some five years ago with 30 partners from 10 EU member states, two associated countries (Norway, Israel) and one international cooperation partner country (Chile), has been the close cooperation between research groups and enterprises; more or less equally represented in this large consortium. In this respect, TargetFish has been revolutionary validating by this close cooperation fundamental knowledge for the development of next generation vaccines and different routes of vaccine administration. TargetFish had the ambition to demonstrate market applicability of improved vaccines or new prototype vaccines that would come forward from the project. Via frequent joint meetings of its partners, be it research group or enterprise, TargetFish aimed to drive vaccine development in an industrial applicable way. This could facilitate adoption of new intellectual property and stimulate the presentation of new fish vaccines on the market. The industry forum has been a platform for a continuing validation of the applied potential of the research outcomes. Workshops were organised at the different EAFP meetings to communicate the validation process to those not directly involved with the project but interested in the fish vaccine market. After a kick-off meeting during the EAFP in Tampere, Finland fours years ago and a second meeting at the EAFP in Las Palmas, Spain, two years ago, at the present EAFP in Belfast, Northern Ireland a final meeting was organised. This report is a summary of the 'Industrial Forum workshop' held at the EAFP in Belfast 2017 and provides a short overview of the highlights presented to, and discussed with, those present and interested in DNA vaccine development, policies and laws, production and delivery routes.

M3 - Journal article

VL - 38

SP - 116

EP - 121

JO - Bulletin of The European Association of Fish Pathologists

JF - Bulletin of The European Association of Fish Pathologists

SN - 0108-0288

IS - 3

ER -